Table 4 Immunoexpression of ANKRD55 protein in various pediatric CNS tumors
Tumor entity | > 75% | 25–74% | 1–24% | Negative |
|---|---|---|---|---|
CNS neuroblastoma with FOXR2 activation (n = 20) | 100% | 0 | 0 | 0 |
Pediatric glioblastoma with G34 mutation (n = 25) | 0 | 0 | 0 | 100% |
Pediatric glioblastoma; MYCN (n = 20) | 0 | 0 | 0 | 100% |
Supratentorial ependymoma; RELA fusion (n = 40) | 0 | 0 | 0 | 100% |
Diffuse midline glioma, H3 K27-altered (n = 30) | 0 | 0 | 0 | 100% |
Pediatric glioblastoma, RTKI (pGBM_MID; n = 30) | 0 | 0 | 0 | 100% |
Pediatric glioblastoma, RTKIII (n = 12) | 0 | 0 | 0 | 100% |
Adult glioblastoma, IDH-wildtype (n = 40) | 0 | 0 | 0 | 100% |
Adult glioblastoma; IDH-mutant (n = 20) | 0 | 0 | 0 | 100% |
Anaplastic oligodendroglioma, IDH-mutant (n = 20) | 0 | 0 | 0 | 100% |
Embryonal tumor with multilayered rosettes (n = 30) | 0 | 0 | 30% | 70% |
Atypical teratoid/rhabdoid tumor (n = 20) | 0 | 0 | 0 | 100% |
CNS neuroepithelial tumor; MN1-altered (n = 18) | 0 | 0 | 0 | 100% |
CNS neuroepithelial tumor; BCOR-altered (n = 8) | 0 | 0 | 0 | 100% |
CNS neuroepithelial tumor; CIC-altered (n = 5) | 0 | 0 | 0 | 100% |
Intracranial Ewing sarcoma (n = 4) | 0 | 0 | 0 | 100% |
Diffuse leptomeningeal glioneuronal tumor (n = 5) | 0 | 0 | 0 | 100% |